Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Opinion Article

Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset Autoimmune Diabetes in Adults: A Concise Review

Author(s): Lakshmi Chandran, Ankul Singh S. and Chitra Vellapandian*

Volume 19, Issue 1, 2023

Published on: 26 April, 2022

Article ID: e240322202561 Pages: 9

DOI: 10.2174/1573399818666220324095918

Price: $65

Abstract

Latent Onset Autoimmune Diabetes in Adults (LADA) is an autoimmune disorder between T1DM and T2DM and is often misdiagnosed as T2DM due to its late-onset. The disease is characterized by β-cell failure and slow progression to insulin dependence. Early diagnosis is significant in limiting disease progression. C-peptide levels and autoantibodies against β-cells are the most critical diagnostic biomarkers in LADA. The review aims to provide an overview of the biomarkers used to diagnose LADA, and the following treatment approaches. We have summarized LADA's pathophysiology and the autoantibodies involved in the condition, diagnostic approaches, and challenges. There are clear shortcomings concerning the feasibility of autoantibody testing. Finally, we have explored the treatment strategies involved in the management of LADA.

In conclusion, the usual management includes treatment with metformin and the addition of low doses of insulin. Newer oral hypoglycaemic agents, such as GLP-1RA and DPP-4 inhibitors, have been brought into use. Since the disease is not entirely understood at the research level and in clinical practice, we hope to encourage further research in this field to assess its prevalence. Large randomized controlled trials are required to compare the efficacy of different available treatment options.

Keywords: LADA, autoimmune disorder, C-peptide, biomarkers, autoantibodies LADA, autoantibodies.

[1]
Duvnjak L, Blaslov K. Vučić Lovrenčić M, Knežević Ćuća J. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. Diabetes Res Clin Pract 2016; 121: 119-26.
[http://dx.doi.org/10.1016/j.diabres.2016.09.013] [PMID: 27693949]
[2]
Chen W, Chen X, Zhang M, Huang Z. The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of Latent Autoimmune Diabetes of Adults (LADA): Evidence based on available data. Gene 2021; 767: 145177.
[http://dx.doi.org/10.1016/j.gene.2020.145177] [PMID: 32998048]
[3]
Maddaloni E, Moretti C, Mignogna C, Buzzetti R. Adult-onset autoimmune diabetes in 2020: An update. Maturitas 2020; 137: 37-44.
[http://dx.doi.org/10.1016/j.maturitas.2020.04.014] [PMID: 32498935]
[4]
Poojith N, Kumar Rathinam K, Sabarathinam S. Progression of type-2 diabetes mellitus associated with pulmonary tuberculosis sequelae in a 60-year-old hypertensive patient: A multifactorial case report with literature review. Act Scie Pharma 2020; 4(10): 12-4.
[http://dx.doi.org/10.31080/ASPS.2020.04.0590]
[5]
Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 2019; 15(11): 635-50.
[http://dx.doi.org/10.1038/s41574-019-0254-y] [PMID: 31534209]
[6]
Moosaie F, Meftah N, Deravi N, et al. Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences. Prim Care Diabetes 2021; 15(1): 169-74.
[http://dx.doi.org/10.1016/j.pcd.2020.07.008] [PMID: 32798203]
[7]
Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36(4): 908-13.
[http://dx.doi.org/10.2337/dc12-0931] [PMID: 23248199]
[8]
Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53(12): 3193-200.
[http://dx.doi.org/10.2337/diabetes.53.12.3193] [PMID: 15561950]
[9]
Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab 2018; 29(9): 638-50.
[http://dx.doi.org/10.1016/j.tem.2018.07.001] [PMID: 30041834]
[10]
Pozzilli P, Pieralice S. Latent autoimmune diabetes in adults: Current status and new horizons. Endocrinol Metab (Seoul) 2018; 33(2): 147-59.
[http://dx.doi.org/10.3803/EnM.2018.33.2.147] [PMID: 29947172]
[11]
Kumar A, de Leiva A. Latent autoimmune diabetes in adults in North Indian Region: Assessment of β-cell function, metabolic and immunological features. Metab Syndr Relat Disord 2017; 15(10): 494-9.
[http://dx.doi.org/10.1089/met.2017.0103] [PMID: 29040050]
[12]
Sabarathinam S, Rajanandh MG, Seenivasan P. Prevalence of metabolic syndrome in diabetic patients attending a diabetic clinic in a tertiary care hospital. Drug Invention Today 2019; 12(7): 1395-8.
[13]
Brahmkshatriya PP, Mehta AA, Saboo BD, Goyal RK. Characteristics and prevalence of Latent Autoimmune Diabetes in Adults (LADA). ISRN Pharmacol 2012; 2012: 580202.
[http://dx.doi.org/10.5402/2012/580202] [PMID: 22577577]
[14]
Murao S, Kondo S, Ohashi J, et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)--a 5-year follow-up of the Ehime study. Diabetes Res Clin Pract 2008; 80(1): 114-21.
[http://dx.doi.org/10.1016/j.diabres.2008.01.024] [PMID: 18342387]
[15]
Yang Z, Zhou Z, Huang G, et al. The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract 2007; 76(1): 126-31.
[http://dx.doi.org/10.1016/j.diabres.2006.08.013] [PMID: 17005288]
[16]
Pieralice S, Pozzilli P. Latent autoimmune diabetes in adults: A review on clinical implications and management. Diabetes Metab J 2018; 42(6): 451-64.
[http://dx.doi.org/10.4093/dmj.2018.0190] [PMID: 30565440]
[17]
Huang J, Pearson JA, Wong FS, Wen L, Zhou Z. Innate immunity in latent autoimmune diabetes in adults. Diabetes Metab Res Rev 2021; e3480.
[http://dx.doi.org/10.1002/dmrr.3480] [PMID: 34156143]
[18]
Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005; 12(6): 580-91.
[http://dx.doi.org/10.1097/01.mjt.0000178767.67857.63] [PMID: 16280652]
[19]
Uibo R, Lernmark A. GAD65 autoimmunity-clinical studies. Adv Immunol 2008; 100: 39-78.
[http://dx.doi.org/10.1016/S0065-2776(08)00803-1] [PMID: 19111163]
[20]
Falorni A. Aspetti immunologici e genetici del diabete autoimmune latente dell’adulto. Minerva Endocrinol 2003; 28(4): 297-312.
[PMID: 14752400]
[21]
Ola T, David R, Leslie G. Progression of Autoimmune Diabetes 2006; 1079(1): 81-9.
[22]
Chiu HK, Tsai EC, Juneja R, et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77(2): 237-44.
[http://dx.doi.org/10.1016/j.diabres.2006.12.013] [PMID: 17234296]
[23]
Badal D, Kumar R, Paul M, et al. Peripheral blood mononuclear cells of patients with latent autoimmune diabetes secrete higher levels of pro- & anti-inflammatory cytokines compared to those with type-1 diabetes mellitus following in vitro stimulation with β-cell autoantigens. Indian J Med Res 2017; 145(6): 767-76.
[http://dx.doi.org/10.4103/ijmr.IJMR_1563_15] [PMID: 29067979]
[24]
Hjort R, Ahlqvist E, Andersson T, et al. Physical activity, genetic susceptibility, and the risk of latent autoimmune diabetes in adults and type 2 diabetes. J Clin Endocrinol Metab 2020; 105(11): 105.
[http://dx.doi.org/10.1210/clinem/dgaa549] [PMID: 32835373]
[25]
Carlsson S. Environmental (Lifestyle) risk factors for LADA. Curr Diabetes Rev 2019; 15(3): 178-87.
[http://dx.doi.org/10.2174/1573399814666180716150253] [PMID: 30009710]
[26]
Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000; 278(5): E759-68.
[http://dx.doi.org/10.1152/ajpendo.2000.278.5.E759] [PMID: 10780930]
[27]
Rajkumar V, Levine S. Latent Autoimmune Diabetes [Internet]. Ncbi.nlm.nih.gov. 2021. [cited 12 October 2021]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557897/nlm.nih.gov
[28]
Bell DS, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am J Ther 2004; 11(4): 308-11.
[http://dx.doi.org/10.1097/01.mjt.0000102372.28723.2b] [PMID: 15266224]
[29]
Laugesen E, Østergaard JA, Leslie RD. Latent autoimmune diabetes of the adult: Current knowledge and uncertainty. Diabet Med 2015; 32(7): 843-52.
[http://dx.doi.org/10.1111/dme.12700] [PMID: 25601320]
[30]
Sørgjerd E. Type 1 diabetes-related autoantibodies in different forms of Diabetes. Curr Diabetes Rev 2018; 15(3): 199-204.
[PMID: 30058495]
[31]
Mallone R, Ortolan E, Pinach S, et al. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and Latent Autoimmune Diabetes of the Adult (LADA) and comparison with other islet autoantibodies. Diabetologia 2002; 45(12): 1667-77.
[http://dx.doi.org/10.1007/s00125-002-0940-4] [PMID: 12488956]
[32]
Jin P, Huang G, Lin J, Luo S, Zhou Z. Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol 2011; 48(2): 149-55.
[http://dx.doi.org/10.1007/s00592-010-0250-0] [PMID: 21212992]
[33]
Li X, Zhou ZG, Huang G, et al. Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann N Y Acad Sci 2004; 1037: 122-6.
[http://dx.doi.org/10.1196/annals.1337.019] [PMID: 15699504]
[34]
Desai M, Clark A. Autoimmune diabetes in adults: Lessons from the UKPDS. Diabet Med 2008; 25 (Suppl. 2): 30-4.
[http://dx.doi.org/10.1111/j.1464-5491.2008.02497.x] [PMID: 18717976]
[35]
Myers MA, Rabin DU, Rowley MJ. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 1995; 44(11): 1290-5.
[http://dx.doi.org/10.2337/diab.44.11.1290] [PMID: 7589826]
[36]
Li R, Huang J, Yu Y, Yang Y. islet autoantibody patterns in patients with type 2 diabetes aged 60 and higher: A cross-sectional study in a Chinese Hospital. Front Endocrinol (Lausanne) 2018; 9: 260.
[http://dx.doi.org/10.3389/fendo.2018.00260] [PMID: 29887833]
[37]
Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52(5): 1137-42.
[http://dx.doi.org/10.2337/diabetes.52.5.1137] [PMID: 12716743]
[38]
Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005; 54 (Suppl. 2): S52-61.
[http://dx.doi.org/10.2337/diabetes.54.suppl_2.S52] [PMID: 16306341]
[39]
Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998; 161(5): 2648-54.
[PMID: 9725268]
[40]
Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 48(4): 703-8.
[http://dx.doi.org/10.1007/s00125-005-1691-9] [PMID: 15765222]
[41]
Siljander H, Härkönen T, Hermann R, et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009; 25(7): 615-22.
[http://dx.doi.org/10.1002/dmrr.998] [PMID: 19637309]
[42]
Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005; 19(1): 119-33.
[http://dx.doi.org/10.1016/j.beem.2004.11.010] [PMID: 15826926]
[43]
Davidson HW, Wenzlau JM, O’Brien RM. Zinc transporter 8 (ZnT8) and β cell function. Trends Endocrinol Metab 2014; 25(8): 415-24.
[http://dx.doi.org/10.1016/j.tem.2014.03.008] [PMID: 24751356]
[44]
Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010; 33(1): 104-8.
[http://dx.doi.org/10.2337/dc08-2305] [PMID: 19808923]
[45]
Hussein H, Ibrahim F, Sobngwi E, Gautier JF, Boudou P. Zinc transporter 8 autoantibodies assessment in daily practice. Clin Biochem 2017; 50(1-2): 94-6.
[http://dx.doi.org/10.1016/j.clinbiochem.2016.06.008] [PMID: 27363941]
[46]
Gambelunghe G, Forini F, Laureti S, et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000; 52(5): 565-73.
[http://dx.doi.org/10.1046/j.1365-2265.2000.00983.x] [PMID: 10792335]
[47]
Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002; 45(9): 1298-306.
[http://dx.doi.org/10.1007/s00125-002-0886-6] [PMID: 12242463]
[48]
Pham MN, Hawa MI, Pfleger C, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011; 54(7): 1630-8.
[http://dx.doi.org/10.1007/s00125-011-2088-6] [PMID: 21347621]
[49]
Schloot NC, Pham MN, Hawa MI, et al. Inverse relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: Action LADA 11. Diabetes Care 2016; 39(11): 1932-9.
[http://dx.doi.org/10.2337/dc16-0293] [PMID: 27573939]
[50]
Strom A, Menart B, Simon MC, et al. Cellular interferon-γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: Action LADA 6. Cytokine 2012; 58(2): 148-51.
[http://dx.doi.org/10.1016/j.cyto.2012.01.002] [PMID: 22305546]
[51]
O’Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr 2016; 29(4): 249-52.
[http://dx.doi.org/10.2337/ds15-0047] [PMID: 27899877]
[52]
Chatzianagnostou K, Iervasi G, Vassalle C. Challenges of LADA diagnosis and treatment: Lessons from 2 case reports. Am J Ther 2016; 23(5): e1270-4.
[http://dx.doi.org/10.1097/MJT.0000000000000349] [PMID: 26422824]
[53]
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: Current knowledge and implications for management. Nat Rev Endocrinol 2017; 13(11): 674-86.
[http://dx.doi.org/10.1038/nrendo.2017.99] [PMID: 28885622]
[54]
Hernández M, Mauricio D. Latent autoimmune diabetes in adults: a review of clinically relevant issues. Adv Exp Med Biol 2021; 1307: 29-41.
[http://dx.doi.org/10.1007/5584_2020_533] [PMID: 32424495]
[55]
Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes 2020; 69(10): 2037-47.
[http://dx.doi.org/10.2337/dbi20-0017] [PMID: 32847960]
[56]
Rajkumar V, Levine SN. Stat Pearls [Internet]. Latent Autoimmune Diabetes 2021. Jul 18 [cited 2021 Dec 24]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK557897/
[57]
Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab 2021; 106(1): 237-50.
[http://dx.doi.org/10.1210/clinem/dgaa710] [PMID: 33034350]
[58]
Fedotkina O, Sulaieva O, Ozgumus T, et al. Novel reclassification of adult diabetes is useful to distinguish stages of β-cell function linked to the risk of vascular complications: The DOLCE Study from Northern Ukraine. Front Genet 2021; 12: 637945.
[http://dx.doi.org/10.3389/fgene.2021.637945] [PMID: 34276762]
[59]
Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent Autoimmune Diabetes of Adults (LADA) is likely to represent a mixed population of autoimmune (type 1) and nonautoimmune (type 2) diabetes. Diabetes Care 2021; 44(6): 1243-51. [Internet]
[http://dx.doi.org/10.2337/dc20-2834] [PMID: 34016607]
[60]
Andersen CD, Bennet L, Nyström L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 2013; 56(2): 252-8.
[http://dx.doi.org/10.1007/s00125-012-2759-y] [PMID: 23096095]
[61]
Thunander M, Thorgeirsson H, Törn C, Petersson C, Landin-Olsson M. β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: A 3-year follow-up. Eur J Endocrinol 2011; 164(2): 239-45.
[http://dx.doi.org/10.1530/EJE-10-0901] [PMID: 21088056]
[62]
Cernea S, Buzzetti R, Pozzilli P. β-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009; 32 (Suppl. 2): S246-52.
[http://dx.doi.org/10.2337/dc09-S317] [PMID: 19875559]

Rights & Permissions Print Cite
Article Metrics
8
© 2024 Bentham Science Publishers | Privacy Policy